20:47 , Jul 12, 2019 |  BC Extra  |  Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a differentiated patient population following the approval of two...
00:09 , Jun 25, 2019 |  BC Extra  |  Company News

Otezla divestiture makes next launches mission critical for BMS

The molecule that started Celgene's market decline, leading to its eventual takeout, is now being off-loaded to allow BMS to close the deal. Losing it from the line-up will raise the pressure for successful launches...
21:29 , Jun 21, 2019 |  BioCentury  |  Emerging Company Profile

Arcutis: Reformulating dermatology

Arcutis Inc. is using its founders' topical reformulation expertise to develop safer and less expensive therapeutics against known targets to treat dermatology patients who aren't eligible for biologics. Frazier Healthcare launched the company in 2016...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
18:35 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
01:06 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection; graft rejection Mouse studies suggest inhibiting CORO1A or its downstream mediator PDE-4 could help treat heart transplant and skin graft rejection. In a mouse model of heart transplantation, systemic CORO1A knockout...
17:21 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Celgene's Otezla meets in Phase III for scalp psoriasis

Celgene Corp. (NASDAQ:CELG) said Otezla apremilast met the primary endpoint in the Phase III STYLE trial to treat moderate to severe plaque psoriasis of the scalp. A significantly greater proportion of patients who received twice-daily...
19:33 , Jun 1, 2018 |  BC Week In Review  |  Company News

vTv, Newsoara in PDE-4 deal

vTv Therapeutics Inc. (NASDAQ:VTVT) granted Newsoara Biopharma Co. Ltd. (Shanghai, China) development and commercialization rights to HPP737 in China, including Hong Kong and Macau, and Taiwan as well as other Asian countries. vTv will receive...
18:48 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from 51 amyotrophic lateral sclerosis (ALS) patients without non-invasive ventilation in a Phase Ib/IIa trial showing that once-daily 60 mg oral ibudilast (Ketas, AV411, MN-166) plus riluzole non-significantly...
18:47 , May 4, 2018 |  BC Week In Review  |  Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) reported additional data from the Phase IIb SPRINT-MS trial in 255 patients with primary or secondary progressive multiple sclerosis showing that twice-daily oral ibudilast (Ketas, AV411, MN-166) met the secondary endpoint...